Pulmatrix: $0 revenue in 2025, net loss $5.2M, plans to license iSPERSE

Pulmatrix, Inc.

2025-FY EPS reported -$1.41

Revenue $0 in 2025 vs $7.8M in 2024; net loss $5.2M ($1.41/share) vs $9.6M.
Cash and equivalents $4.1M at Dec 31, 2025, down from $9.5M; cash runway into Q1 2027.
Plans to license or monetize iSPERSE platform and migraine asset PUR3100.
Proposed merger with Cullgen pending CSRC approval; 'No Solicitation' clause waived to explore alternatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.